ArticleBritish journal of cancer2020
Fatal prostate cancer incidence trends in the United States and England by race, stage, and treatment.
Article in British journal of cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 49 citations in OpenAlex.
- A Critical Literature Review of Health Inequalities, Cultural Exclusion, and the Case for a Culturally Appropriate Digital Health Promotion App for Black Communities in England.Healthcare (Basel, Switzerland) · 2026Review
- Early-Onset Prostate Cancer: Epidemiology, Risk Factors, Biology, Clinical Features, Management, and Early Detection.MedComm · 2026Review
- Prostate Cancer, JAK/STAT3 Dysregulation, and Flavonoids: Is There a Possible Link?International journal of molecular sciences · 2026Review
- Temporal trends and regional disparities in prostate cancer mortality in the United States, 1999-2023: an analysis of the CDC WONDER database.BMC public health · 2025Article
- Global, regional, and national burden and trends of prostate cancer in elderly from 1990 to 2021: results from global burden of disease 2021.World journal of surgical oncology · 2025Article
- Racial disparities in prostate cancer in the UK and the USA: similarities, differences and steps forwards.Nature reviews. Urology · 2025Review
- Global burden of prostate cancer: age-period-cohort analysis from 1990 to 2021 and projections until 2040.World journal of surgical oncology · 2025Article
- Incidence, Prevalence, and Survival of Prostate Cancer in the UK.JAMA network open · 2024Article
- Demographic bias in misdiagnosis by computational pathology models.Nature medicine · 2024Article
- Association between patient ethnicity and prostate cancer diagnosis following a prostate-specific antigen test: a cohort study of 730,000 men in primary care in the UK.BMC medicine · 2024Article
- Article
- Human herpesvirus 8 infection is associated with prostate cancer among IFNL4-ΔG carriers.Prostate cancer and prostatic diseases · 2023Article
- Systemic Inflammation Indices and Association with Prostate Cancer Survival in a Diverse Patient Cohort.Cancers · 2023Article
- A machine learning framework develops a DNA replication stress model for predicting clinical outcomes and therapeutic vulnerability in primary prostate cancer.Journal of translational medicine · 2023Article
- Serum PSA-based early detection of prostate cancer in Europe and globally: past, present and future.Nature reviews. Urology · 2022Review
- Serum proteomics links suppression of tumor immunity to ancestry and lethal prostate cancer.Nature communications · 2022Article
- Immune response and inflammation in cancer health disparities.Trends in cancer · 2022Review
- Urinary Thromboxane B2 and Lethal Prostate Cancer in African American Men.Journal of the National Cancer Institute · 2022Article
- The most effective but largely ignored target for prostate cancer early detection and intervention.Journal of Cancer · 2022Article
- Immune Inflammation Pathways as Therapeutic Targets to Reduce Lethal Prostate Cancer in African American Men.Cancers · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundDifferential uptake of prostate-specific antigen testing in the US and UK has been linked to between-country differences for prostate cancer incidence. We examined stage-specific fatal prostate cancer incidence trends in the US and England, by treatment and race/ethnicity.
methodsUsing data from the National Cancer Institute's Surveillance, Epidemiology, and End Results program and Public Health England's National Cancer Registration and Analysis Service, we identified prostate cancer patients diagnosed between 1995 and 2005, aged 45-84 years. Fatal prostate cancer was defined as death attributed to the disease within 10 years of diagnosis. We used age-period-cohort models to assess trends in fatal prostate cancer incidence.
resultsFatal prostate cancer incidence declined in the US by -7.5% each year and increased in England by 7.7% annually. These trends were primarily driven by locoregional disease in the US and distant disease in England. Black men in both countries had twofold to threefold higher fatal prostate cancer incidence rates, when compared with their white counterparts; however, receipt of radical prostatectomy lessened this disparity.
conclusionsWe report a significant increasing rate of fatal prostate cancer incidence among English men. The black-white racial disparity appears pervasive but is attenuated among those who received radical prostatectomy in the US.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.